Dec 29, 2021, Shanghai – Mabwell, an innovative biopharmaceutical company with the whole industrial chain, announced that the first person dosed in the Phase I study of anti-ST2 antibody (R&D code: 9MW1911) in China. 9MW1911 is the first antibody directed against the target of ST2 to conduct clinical trials in China. Until now, there’s no antibody drug against the same target has been marketed in the worldwide.

The study (CTR20212590) is a single center trial in healthy people in China. It primarily evaluated the safety and tolerability of 9MW1911 which acts on healthy people and determine the maximum tolerated dose. And next to estimate pharmacokinetics and immunogenicity.

9MW1911 is an innovative humanized monoclonal antibody drug independently developed by Mabwell, a domestic pharmaceutical company in China. The drug’s antibody molecule is derived based on the B-lymphocyte screening platform, and the product is characterized by higher binding affinity and potent biological activity. Nonclinical studies have shown that the in vivo mechanism of action of this product in animals was definite and clear. After binding specifically to the target ST2, it blocks the activation of ST2-mediated signaling pathway induced by cytokine IL-33, hence inhibiting the inflammatory reactions and achieving therapeutic effects in multiple auto-immune diseases.

Dr. Datao Liu, Co-founder & CEO of Mabwell, said, “9MW1911 is first anti-ST2 antibody applied to human in the clinical study in China, which indicates Mabwell’s capability and determination to be ‘First-in-China’. We will continue to strengthen our original innovation capabilities. Mabwell aims to be the 'First in Human' and provide new treatment options for more patients.”